Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials.

ABSTRACT:

Background

We evaluated the validity of surrogacy of progression-free survival (PFS) or time-to-progression (TTP) and overall response rate (ORR) in phase II trials of pancreatic ductal adenocarcinoma (PDAC). In addition, we explored the impact of predictive variables on overall survival (OS) and developed an optimal OS model.

Methods

We analyzed 1867 clinical endpoint from 619 phase II PDAC trials with a systematic search from PubMed. Endpoint correlations were determined by Spearman's rank correlation. The assessed predictive factors included PFS/TTP, treatment size, therapy type, stage, and previous treatment. The relationship between predictors and OS was explored by a gamma generalized linear model (GLM) with a log-link function and compared with linear models.

Resul

SUBMITTER: Kabir ER 

PROVIDER: S-EPMC11465028 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature